ReviewSeminars in immunopathology2022
Age as a risk factor in vasculitis.
Review in Seminars in immunopathology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 1 synthesis or guideline pooled it, 39 citations in OpenAlex.
- Cross-Trait Meta-Analysis Reveals a Genetic Link between Inflammation and Aging in Giant Cell Arteritis.Aging and disease · 2025Pooled it
- How age and sex interaction is associated with immune aging with implications for vaccines and age-related autoimmunity.npj aging · 2026Review
- Hypoxia-Associated Molecular Subtypes Reveal Immune Checkpoint, Ferroptosis, and m6A Regulatory Heterogeneity in Pediatric Vasculitis.Human mutation · 2026Article
- Focusing on Older Adults With Antineutrophil Cytoplasmic Autoantibody-Negative Pauci-Immune Glomerulonephritis.Kidney international reports · 2025Article
- Glycosylation Regulation by TMEM230 in Aging and Autoimmunity.International journal of molecular sciences · 2025Article
- AI-Based Hematological Age Predictors and the Association Between Biological Age Acceleration and Type 2 Diabetes Mellitus - Chongqing Municipality, China, 2015-2021.China CDC weekly · 2024Article
- Immune checkpoints in autoimmune vasculitis.Best practice & research. Clinical rheumatology · 2024Review
- Aging in Ocular Blood Vessels: Molecular Insights and the Role of Oxidative Stress.Biomedicines · 2024Review
- Advances and challenges in management of large vessel vasculitis.Rheumatology and immunology research · 2023Article
- Stem-like CD4Science translational medicine · 2023Article
- Immune aging - A mechanism in autoimmune disease.Seminars in immunology · 2023Review
- Venous, Arterial, and Neuropathic Leg Ulcers With Emphasis on the Geriatric Population.Cureus · 2023Review
- Immunology of Giant Cell Arteritis.Circulation research · 2023Review
- Distinct gene signatures of monocytes and B cells in patients with giant cell arteritis: a longitudinal transcriptome analysis.Arthritis research & therapy · 2023Article
- Use of high-plex data provides novel insights into the temporal artery processes of giant cell arteritis.Frontiers in immunology · 2023Article
- "Listen to Your Immune System When It's Calling for You": Monitoring Autoimmune Diseases Using the iShU App.Sensors (Basel, Switzerland) · 2022Article
- Diseases of blood vessels: Immune system involvement in vasculitis and vasculopathy.Seminars in immunopathology · 2022Article
- Frailty assessment in ANCA-associated vasculitis: current evidence and remaining uncertainties.Rheumatology advances in practice · 2022Article
- T-Cell Aging-Associated Phenotypes in Autoimmune Disease.Frontiers in aging · 2022Review
- Vasculitogenic T Cells in Large Vessel Vasculitis.Frontiers in immunology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
Abstract
Two vasculitides, giant cell arteritis (GCA) and Takayasu arteritis (TAK), are recognized as autoimmune and autoinflammatory diseases that manifest exclusively within the aorta and its large branches. In both entities, the age of the affected host is a critical risk factor. TAK manifests during the 2nd-4th decade of life, occurring while the immune system is at its height of performance. GCA is a disease of older individuals, with infrequent cases during the 6th decade and peak incidence during the 8th decade of life. In both vasculitides, macrophages and T cells infiltrate into the adventitia and media of affected vessels, induce granulomatous inflammation, cause vessel wall destruction, and reprogram vascular cells to drive adventitial and neointimal expansion. In GCA, abnormal immunity originates in an aged immune system and evolves within the aged vascular microenvironment. One hallmark of the aging immune system is the preferential loss of CD8
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.